EP0652888A4 - INHIBITION OF -i(CANDIDA). - Google Patents

INHIBITION OF -i(CANDIDA).

Info

Publication number
EP0652888A4
EP0652888A4 EP19910916648 EP91916648A EP0652888A4 EP 0652888 A4 EP0652888 A4 EP 0652888A4 EP 19910916648 EP19910916648 EP 19910916648 EP 91916648 A EP91916648 A EP 91916648A EP 0652888 A4 EP0652888 A4 EP 0652888A4
Authority
EP
European Patent Office
Prior art keywords
candida
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910916648
Other languages
German (de)
French (fr)
Other versions
EP0652888A1 (en
Inventor
Glenn D Hoke
David J Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP0652888A4 publication Critical patent/EP0652888A4/en
Publication of EP0652888A1 publication Critical patent/EP0652888A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
EP91916648A 1990-08-16 1991-08-15 INHIBITION OF $i(CANDIDA) Withdrawn EP0652888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56867290A 1990-08-16 1990-08-16
US568672 1990-08-16
PCT/US1991/005802 WO1992003455A1 (en) 1990-08-16 1991-08-15 INHIBITION OF $i(CANDIDA)

Publications (2)

Publication Number Publication Date
EP0652888A4 true EP0652888A4 (en) 1993-09-23
EP0652888A1 EP0652888A1 (en) 1995-05-17

Family

ID=24272249

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91916648A Withdrawn EP0652888A1 (en) 1990-08-16 1991-08-15 INHIBITION OF $i(CANDIDA)

Country Status (6)

Country Link
EP (1) EP0652888A1 (en)
JP (1) JPH0779704B2 (en)
AU (1) AU649734B2 (en)
BR (1) BR9106752A (en)
CA (1) CA2089665A1 (en)
WO (1) WO1992003455A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055101A1 (en) 1995-09-11 2002-05-09 Michel G. Bergeron Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
DE19654946A1 (en) * 1996-10-22 1998-05-07 Univ Eberhard Karls Detecting fungi resistant to azole antimycotics in clinical samples
DE19643486C1 (en) * 1996-10-22 1998-12-03 Univ Eberhard Karls Detection of resistant fungal cells in clinical material
FR2755145B1 (en) * 1996-10-28 1999-01-15 Gervais Danone Co PROCESS FOR DEMONSTRATING LIVE MICROBIOLOGICAL CONTAMINANTS IN A SAMPLE OF A PRODUCT FOR FOOD USE
US20030049636A1 (en) 1999-05-03 2003-03-13 Bergeron Michel G. Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
AU741017B2 (en) * 1997-06-10 2001-11-22 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6096511A (en) * 1997-06-10 2000-08-01 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
GB9719044D0 (en) * 1997-09-08 1997-11-12 Inst Of Ophthalmology Assay
BR0014370A (en) 1999-09-28 2002-11-05 Infectio Diagnostic Inc Highly conserved genes and their use to generate species-specific, genus-specific, family-specific, group-specific and universal amplifier probes and species-specific amplifiers to quickly detect and identify algal, amoebic, bacterial, fungal and parasite specimen microorganisms clinics for diagnosis
KR100448877B1 (en) * 2002-08-19 2004-09-18 한국전력공사 Apparatus for reducing COD from flue-gas desulfurization waste by electrochemical oxidation process
US20040203006A1 (en) * 2003-04-11 2004-10-14 Cytokinetics, Inc. Novel beta-tubulin protein of Candida glabrata and methods for its use
EP3931325A1 (en) * 2019-02-28 2022-01-05 Universidade do Minho Antisense oligomers for controlling candida albicans infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
GB9125891D0 (en) * 1991-12-05 1992-02-05 Inst Of Cancer The Research Antiviral agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GENE vol. 72, 1988, AMSTERDAM NL pages 311 - 312 JESSUS, C. ET AL. 'Specific inhibition of beta-tubulin synthesis in Xenopus oocytes using anti-sense oligodeoxyribonucleotides' *
JOURNAL OF BACTERIOLOGY vol. 172, no. 4, April 1990, AMERICAN SOCIETY FOR MICROBIOLOGY pages 2036 - 2045 SUNDSTROM P. ET AL. 'Sequence analysis and expression of the two genes for elongation factor 1alpha from the dimorphic yeast Candida albicans' *
NUCLEIC ACIDS RESEARCH vol. 15, no. 14, 24 July 1987, ARLINGTON, VIRGINIA US pages 5749 - 5763 MARCUS-SEKURA, C. ET AL. 'Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages' *
See also references of WO9203455A1 *

Also Published As

Publication number Publication date
AU8635591A (en) 1992-03-17
JPH0779704B2 (en) 1995-08-30
CA2089665A1 (en) 1992-02-17
EP0652888A1 (en) 1995-05-17
JPH06501844A (en) 1994-03-03
AU649734B2 (en) 1994-06-02
WO1992003455A1 (en) 1992-03-05
BR9106752A (en) 1993-08-17

Similar Documents

Publication Publication Date Title
DE69107059D1 (en) Sigma-delta-modulator.
EP0597463A3 (en) Thermotherapiesonde.
EP0593428A4 (en) Myconematicide.
EP0580285A3 (en) Auto-reclosers.
ZA919660B (en) Alpha-oxoacetamide derivatives.
PH30977A (en) Hiv-inhibiting benzene-acetamide derivatives.
DE69013160D1 (en) Reibscheibentoroidgetriebe.
DE68907587D1 (en) Trappingssystem.
DE69112211D1 (en) Luftreinigungsvorrichtung.
DE69104185D1 (en) Luftreservoir.
DE69106281D1 (en) Phenanthrenderivat.
DE59204008D1 (en) Trachealstent.
EP0652888A4 (en) INHIBITION OF -i(CANDIDA).
EP0572808A3 (en) Antiblocage-system.
ZA926482B (en) Cyanophenylpyrroles.
DE59001953D1 (en) Interferometeranordnung.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
DE59008181D1 (en) Trifluormethylcyclohexan-derivate.
DE69022965D1 (en) Aminopiperazinderivate.
DE69008186D1 (en) Allylhydroperoxidkettenübertragungsmittel.
ZA904897B (en) Vip-analogs ii.
DE59000988D1 (en) Brueckenuntersichtvorrichtung.
DE69002778D1 (en) Pyrolytisches bornitrid.
DE69102644D1 (en) Demodulationsreferenzsignalquelle.
ZA929590B (en) Diphenylsulphides.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930312

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960301